MASS - NASDAQ

908 Devices Inc.

MASS·NASDAQ

$8.66

-2.1%

HealthcareMedical - Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$327.47M

EPS0.5400

P/E Ratio16.04

Earnings Date08/04/2026

190.07M

Assets

19%

3Y-22.0%

5Y+6.0%

10Y+585.0%

46.37M

Total Liabilities

3Y-11.0%

5Y+17.0%

10Y-40.0%

143.70M

Total Equity

25%

3Y-25.0%

5Y+3.0%

10Y-386.0%

908 Devices Inc. Funding & Solvency Profile

MASS · NASDAQ

Current Assets

Cash & Cash Equivalents112.97M

Net Receivables11.33M

Inventory12.99M

Other Current Assets7.27M

Total Current Assets145 M

Non-Current Assets

Property, Plant & Equipment8.63M

Goodwill & Intangible Assets36.41M

Long-Term Investments0.00

Other Non-Current Assets471.00K

Total Non-Current Assets9 M

Total Assets

190.07M

Financial Health Analysis

Current Ratio

4.24x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.32x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

110 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

76% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

908 Devices Inc. Balance Sheet

MASS • NASDAQ

908 Devices Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	113M	44M	121M	188.4M	224.1M	159.2M	17.9M	7.1M
Short-Term Investments	0.0	25.6M	24.6M	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	113M	69.6M	145.7M	188.4M	224.1M	159.2M	17.9M	7.1M
Net Receivables	11.3M	12.6M	9M	10M	16.6M	6.8M	5.1M	6.3M
Accounts Receivables	11.3M	12.6M	9M	10M	16.6M	6.8M	5M	4.1M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	74K	2.2M
Inventory	13M	16.2M	14.9M	12.5M	7.9M	4.6M	5.2M	3.5M
Prepaids	0.0	0.0	0.0	0.0	4.3M	347K	351K	272K
Other Current Assets	7.3M	4.7M	4.2M	4.7M	60K	0.0	0.0	0.0
Total Current Assets	144.6M	103.1M	173.8M	215.6M	252.9M	171M	28.6M	17.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	8.6M	10.3M	9.6M	7M	6.8M	7.1M	8.6M	10M
Goodwill	0.0	0.0	10.4M	10.1M	0.0	0.0	0.0	0.0
Intangible Assets	36.4M	45.3M	7.9M	8.5M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	36.4M	45.3M	18.2M	18.5M	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	171K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	471K	829K	1.2M	1.4M	1.2M	723K	511K	531K
Total Non-Current Assets	45.5M	56.4M	29.2M	27M	8M	7.9M	9.1M	10.5M
Total Assets	190.1M	159.5M	203M	242.6M	260.9M	178.8M	37.7M	27.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	8.4M	2.1M	1.2M	1.4M	1.4M	1M	577K	645K
Accounts Payable	8.4M	2.1M	1.2M	1.4M	1.4M	1M	577K	645K
Accrued Expenses	0.0	0.0	6M	4.9M	5.4M	3M	1M	1M
Short Term Debt	16.7M	1.9M	2M	0.0	0.0	500K	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	0.0	1.5M	1.3M	1.2M	1.1M	310K
Deferred Revenue	8.9M	12.1M	10.6M	7.5M	0.0	3.1M	1.5M	951K
Other Current Liabilities	0.0	9.1M	2.7M	3.9M	6.8M	2.1M	1.9M	1.8M
Total Current Liabilities	34.1M	25.1M	22.5M	19.2M	14.8M	10.8M	6.1M	4.8M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	15M	15M	14.3M	14.8M	9.7M
Deferred Revenue (Non-Current)	8.3M	10.7M	8.6M	11.5M	0.0	8.6M	571K	362K
Deferred Tax Liabilities (Non-Current)	0.0	2M	2.4M	2.7M	0.0	0.0	71.7M	-8.1M
Other Non-Current Liabilities	4M	2.3M	0.0	555K	12M	194K	72.5M	55.2M
Total Non-Current Liabilities	12.3M	19.7M	14.9M	32.8M	31.5M	29M	94.8M	73.2M
Capital Lease Obligations	0.0	4.7M	3.9M	4.5M	5.9M	7M	8M	8.3M
Total Liabilities	46.4M	44.9M	37.5M	52M	46.3M	39.8M	100.8M	77.9M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	-2.5M	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	71M	53.1M
Common Stock	36K	35K	33K	32K	31K	27K	5K	5K
Additional Paid-In Capital	0.0	0.0	334.7M	324M	315.2M	217.5M	2.5M	2.1M
Retained Earnings	-223.3M	-242.8M	-170.6M	-134.2M	-100.6M	-78.5M	-65.6M	-52.3M
Accumulated Other Comprehensive Income/Loss	54K	1.1M	1.4M	798K	0.0	0.0	-65.6M	-2.5M
Other Total Stockholders' Equity	366.9M	356.2M	0.0	0.0	0.0	0.0	-2.9M	-50.6M
Total Stockholders' Equity	143.7M	114.6M	165.5M	190.6M	214.6M	139M	-63.2M	-50.2M
Total Equity	143.7M	114.6M	165.5M	190.6M	214.6M	139M	-63.2M	-50.2M
SUMMARY
Total Liabilities & Equity	190.1M	159.5M	203M	242.6M	260.9M	178.8M	37.7M	27.7M
Total Investments	0.0	25.6M	24.8M	0.0	0.0	0.0	0.0	0.0
Total Debt	16.7M	6.6M	5.9M	19.5M	20.9M	21.9M	22.8M	17.9M
Net Debt	-96.3M	-37.4M	-115.1M	-168.9M	-203.2M	-137.4M	4.9M	10.9M
Shares Outstanding	36,085,698	36,085,698	36,085,698	36,085,698	36,085,698	36,085,698	36,085,698	36,085,698

SEC Filings

MASS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 11, 2026	2026	View Filing
S-3 S-3 N/A	March 09, 2026	March 09, 2026		View Filing
10-K 10-K 2025 FY FY	March 09, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 20, 2026	January 20, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 10, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 05, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 79 filings

Related Guides

Blog Categories

Continue your MASS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.